Drive Wealth Management LLC Invests $36,000 in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Drive Wealth Management LLC acquired a new position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) during the 4th quarter, Holdings Channel reports. The fund acquired 20,000 shares of the company’s stock, valued at approximately $36,000.

Separately, Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after acquiring an additional 42,376 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $1.77 on Wednesday. Reviva Pharmaceuticals Holdings, Inc. has a twelve month low of $0.60 and a twelve month high of $4.83. The firm’s 50 day moving average price is $1.73 and its two-hundred day moving average price is $1.34. The firm has a market cap of $59.19 million, a P/E ratio of -1.59 and a beta of -0.12.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 price objective on the stock. HC Wainwright reduced their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, January 10th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.